Venturi Wealth Management LLC Buys 297 Shares of Abbott Laboratories (NYSE:ABT)

Venturi Wealth Management LLC lifted its stake in shares of Abbott Laboratories (NYSE:ABT) by 1.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 19,764 shares of the healthcare product maker’s stock after acquiring an additional 297 shares during the quarter. Venturi Wealth Management LLC’s holdings in Abbott Laboratories were worth $1,717,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Usca Ria LLC boosted its stake in shares of Abbott Laboratories by 0.6% during the 4th quarter. Usca Ria LLC now owns 21,532 shares of the healthcare product maker’s stock worth $1,870,000 after acquiring an additional 125 shares in the last quarter. Arizona State Retirement System boosted its stake in shares of Abbott Laboratories by 1.5% during the 4th quarter. Arizona State Retirement System now owns 389,499 shares of the healthcare product maker’s stock worth $33,832,000 after acquiring an additional 5,652 shares in the last quarter. TCI Wealth Advisors Inc. lifted its position in shares of Abbott Laboratories by 1.0% during the 4th quarter. TCI Wealth Advisors Inc. now owns 19,888 shares of the healthcare product maker’s stock worth $1,727,000 after purchasing an additional 197 shares during the last quarter. Birch Capital Management LLC acquired a new position in shares of Abbott Laboratories during the 4th quarter worth about $944,000. Finally, Northern Oak Wealth Management Inc. lifted its position in shares of Abbott Laboratories by 6.4% during the 4th quarter. Northern Oak Wealth Management Inc. now owns 9,169 shares of the healthcare product maker’s stock worth $796,000 after purchasing an additional 553 shares during the last quarter. Institutional investors own 73.58% of the company’s stock.

Abbott Laboratories stock traded down $1.12 during trading hours on Monday, hitting $89.28. The stock had a trading volume of 292,326 shares, compared to its average volume of 5,025,742. The company has a 50-day moving average of $86.90 and a two-hundred day moving average of $84.79. The company has a quick ratio of 1.12, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. The company has a market cap of $159.87 billion, a PE ratio of 43.34, a price-to-earnings-growth ratio of 2.29 and a beta of 1.12. Abbott Laboratories has a fifty-two week low of $68.80 and a fifty-two week high of $92.45.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $0.95 EPS for the quarter, meeting the consensus estimate of $0.95. The firm had revenue of $8.31 billion during the quarter, compared to analysts’ expectations of $8.26 billion. Abbott Laboratories had a return on equity of 18.34% and a net margin of 11.56%. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.81 EPS. As a group, analysts forecast that Abbott Laboratories will post 3.6 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be issued a $0.36 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.32. The ex-dividend date of this dividend is Tuesday, January 14th. This represents a $1.44 annualized dividend and a yield of 1.61%. Abbott Laboratories’s dividend payout ratio is 44.44%.

Several research firms recently weighed in on ABT. William Blair reissued an “underperform” rating on shares of Abbott Laboratories in a research report on Thursday, October 17th. Evercore ISI cut Abbott Laboratories from an “outperform” rating to an “in-line” rating in a research report on Thursday, January 2nd. Guggenheim cut Abbott Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, January 2nd. Credit Suisse Group boosted their price objective on Abbott Laboratories from $95.00 to $98.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, Stifel Nicolaus boosted their price objective on Abbott Laboratories from $95.00 to $104.00 and gave the stock a “buy” rating in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $95.57.

Abbott Laboratories Company Profile

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon.

See Also: How do investors use RSI to grade stocks?

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.